As of 2024-12-13, the EV/EBITDA ratio of Proteome Sciences PLC (PRM.L) is -7.08. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PRM.L's latest enterprise value is 20.53 mil GBP. PRM.L's TTM EBITDA according to its financial statements is -2.90 mil GBP. Dividing these 2 quantities gives us the above PRM.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 25.3x | 16.8x |
| Forward P/E multiples | 8.6x - 12.8x | 9.2x |
| Fair Price | (12.19) - (16.19) | (16.33) |
| Upside | -560.1% - -710.8% | -716.4% |
| Date | EV/EBITDA |
| 2024-12-12 | -7.08 |
| 2024-12-11 | -7.19 |
| 2024-12-10 | -7.19 |
| 2024-12-09 | -7.19 |
| 2024-12-06 | -7.09 |
| 2024-12-05 | -7.20 |
| 2024-12-04 | -7.19 |
| 2024-12-03 | -7.03 |
| 2024-12-02 | -7.10 |
| 2024-11-29 | -7.14 |
| 2024-11-28 | -7.07 |
| 2024-11-27 | -7.08 |
| 2024-11-26 | -7.20 |
| 2024-11-25 | -7.04 |
| 2024-11-22 | -7.19 |
| 2024-11-21 | -7.19 |
| 2024-11-20 | -7.19 |
| 2024-11-19 | -7.03 |
| 2024-11-18 | -7.21 |
| 2024-11-15 | -7.19 |
| 2024-11-14 | -7.14 |
| 2024-11-13 | -7.02 |
| 2024-11-12 | -7.13 |
| 2024-11-11 | -7.19 |
| 2024-11-08 | -7.13 |
| 2024-11-07 | -7.13 |
| 2024-11-06 | -7.14 |
| 2024-11-05 | -7.13 |
| 2024-11-04 | -7.08 |
| 2024-11-01 | -7.14 |
| 2024-10-31 | -6.92 |
| 2024-10-30 | -7.20 |
| 2024-10-29 | -7.17 |
| 2024-10-28 | -7.25 |
| 2024-10-25 | -7.24 |
| 2024-10-24 | -7.24 |
| 2024-10-23 | -7.24 |
| 2024-10-22 | -7.46 |
| 2024-10-21 | -7.46 |
| 2024-10-18 | -7.25 |
| 2024-10-17 | -7.25 |
| 2024-10-16 | -7.20 |
| 2024-10-15 | -7.45 |
| 2024-10-14 | -7.40 |
| 2024-10-11 | -7.29 |
| 2024-10-10 | -7.32 |
| 2024-10-09 | -7.46 |
| 2024-10-08 | -7.41 |
| 2024-10-07 | -7.41 |
| 2024-10-04 | -7.41 |